
Boston Scientific Corporation
NYSE•BSX
CEO: Mr. Michael F. Mahoney
セクター: Healthcare
業種: Medical - Devices
上場日: 1992-05-19
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
連絡先情報
300 Boston Scientific Way, Marlborough, MA, 01752-1234, United States
508-683-4000
時価総額
$110.11B
PER (TTM)
38.1
38.4
配当利回り
--
52週高値
$109.50
52週安値
$73.92
52週レンジ
順位35Top 29.9%
4.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$5.29B+0.00%
直近4四半期の推移
EPS
$0.45+0.00%
直近4四半期の推移
フリーCF
$0.00+0.00%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Strong Q3 Sales Growth Net sales reached $5.065B USD in Q3 2025, marking a 20.3% increase, driven by 19.4% operational growth across segments.
Nine Month Net Income Soars Net income attributable to stockholders for nine months totaled $2.226B USD, significantly up from $1.288B USD prior year.
Operating Cash Flow Jumps Cash provided by operating activities for nine months increased $1.191B USD to $3.170B USD due to higher sales.
Key Segment Sales Expansion Cardiology segment sales grew 24.0% in Q3 2025, led by Electrophysiology and WATCHMAN adoption across the portfolio.
リスク要因
Acquisition Contingent Liability Contingent consideration liability stands at $378M USD as of September 30, 2025, reflecting recent business combinations activity.
Ongoing Litigation Exposure Product liability and IP litigation remain ongoing; adverse outcomes could materially impact operations, liquidity, and financial position.
ACURATE Platform Discontinuation Discontinuation of ACURATE systems resulted in approximately $90M USD pre-tax restructuring charges recognized in nine months 2025.
Regulatory Environment Uncertainty Business faces risks from evolving global regulatory enforcement, including EU MDR and potential changes in trade policies.
見通し
Nalu Medical Acquisition Planned Definitive agreement signed to acquire Nalu Medical for expected upfront cash payment of approximately $533M USD, closing H1 2026.
Continued Electrophysiology Focus Growth driven by Farapulse PFA System adoption in Electrophysiology and continued focus on core portfolio strength.
ERP Implementation Progress Multi-year ERP system implementation is progressing, with significant transition completed for Europe, Middle East, and Africa operations.
Strong Liquidity Position Available liquidity remains strong at $2.750B USD via the 2021 Revolving Credit Facility; no commercial paper outstanding.
同業比較
売上高 (TTM)
MCK$397.96B
HCA$75.60B
PFE$62.58B
粗利益率 (最新四半期)
AMGN81.9%
GILD79.8%
BSX74.5%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| AMGN | $196.36B | 25.5 | 96.7% | 60.3% |
| ABT | $195.42B | 30.1 | 13.2% | 0.0% |
| GILD | $182.67B | 22.6 | 40.7% | 42.6% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.3%
緩やかな成長
4四半期純利益CAGR
-0.3%
収益性の安定
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月21日
EPS:-
|売上高:-
財務レポート
財務データ
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年11月3日|売上高: $5.07B+20.3%|EPS: $0.51+60.1%予想を下回るForm 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年8月1日|売上高: $5.06B+22.8%|EPS: $0.54+145.1%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年5月1日|売上高: $4.66B+20.9%|EPS: $0.46+35.4%予想を下回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年2月18日|売上高: $16.75B+17.6%|EPS: $1.26+16.6%予想を上回るForm 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年11月1日|売上高: $4.21B+19.3%|EPS: $0.32-7.6%予想を下回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月1日|売上高: $4.12B+14.5%|EPS: $0.22+22.1%予想を下回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月1日|売上高: $3.86B+13.8%|EPS: $0.34+61.4%予想を下回るForm 10-K/A - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月21日|売上高: $14.24B+12.3%|EPS: $1.08+140.8%予想を上回る